Society guideline links: Anemia in chronic kidney disease

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

International

●Kidney Disease: Improving Global Outcomes (KDIGO): Clinical practice guideline for anemia in chronic kidney disease (2012)

Canada

●Choosing Wisely Canada: Don't initiate erythropoiesis-stimulating agents (ESAs) in chronic kidney disease (CKD) patients with hemoglobin levels greater than or equal to 100 g/L without symptoms of anemia (2021)

United States

●American Diabetes Association (ADA): Anemia in CKD in primary care – Executive summary (2023)

●Kidney Disease Outcomes Quality Initiative (KDOQI): US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD (2013)

Europe

●European Renal Best Practice (ERBP): A position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines on anaemia management in chronic kidney disease (2013)

●ERBP: A position statement for anaemia management in patients with chronic kidney disease (2009)

United Kingdom

●National Institute for Health and Care Excellence (NICE): Guideline on chronic kidney disease – Assessment and management (2021)